Matches in Nanopublications for { ?s ?p "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP454029.RAIcLJI88txRrxYmhDkjMp02e_caJUQlY1lgGvsFfNdOE130_assertion description "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP454029.RAIcLJI88txRrxYmhDkjMp02e_caJUQlY1lgGvsFfNdOE130_provenance.
- assertion description "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP749030.RAsYkBnoe5ujimI5p6zREf2rxMdh2oIw4zGIaxxiVTdrg130_assertion description "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP749030.RAsYkBnoe5ujimI5p6zREf2rxMdh2oIw4zGIaxxiVTdrg130_provenance.
- NP1075893.RAugYJ-3vKn0YEFDqiCBI7BlSrvtji4aXiH0xlVTVrRPk130_assertion description "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1075893.RAugYJ-3vKn0YEFDqiCBI7BlSrvtji4aXiH0xlVTVrRPk130_provenance.
- NP1075888.RAj_Af9oebwUg93FXs5o5-RtrjeERvKR2WSk8fONLtaso130_assertion description "[Since the mismatch repair component MLH1 is defective in 10-15% of colorectal cancers we have investigated whether MLH1 affects response to the Top1 inhibitor irinotecan, alone or in combination with PARPi.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1075888.RAj_Af9oebwUg93FXs5o5-RtrjeERvKR2WSk8fONLtaso130_provenance.